Selected research
Industry Research
Epidermal Growth Factor Receptor (EGFR) Inhibitor Industry Research Report 2026
Market perspective
The global Epidermal Growth Factor Receptor (EGFR) Inhibitor market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Epidermal Growth Factor Receptor (EGFR) Inhibitor market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Epidermal Growth Factor Receptor (EGFR) Inhibitor market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Epidermal Growth Factor Receptor (EGFR) Inhibitor market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Epidermal Growth Factor Receptor (EGFR) Inhibitor include Novartis AG, Eli Lilly and Co., Amgen Inc., AstraZeneca Plc and F. Hoffmann-La Roche Ltd., among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Epidermal Growth Factor Receptor (EGFR) Inhibitor market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Epidermal Growth Factor Receptor (EGFR) Inhibitor.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Epidermal Growth Factor Receptor (EGFR) Inhibitor Market by Company
Novartis AG
Eli Lilly and Co.
Amgen Inc.
AstraZeneca Plc
F. Hoffmann-La Roche Ltd.
Epidermal Growth Factor Receptor (EGFR) Inhibitor Segment by Type
Colorectal Cancer
Lung Cancer
Breast Cancer
Others
Epidermal Growth Factor Receptor (EGFR) Inhibitor Segment by Application
Clinic
Hospital
Research Institutes and Research Institutions
Other
Epidermal Growth Factor Receptor (EGFR) Inhibitor Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Epidermal Growth Factor Receptor (EGFR) Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Epidermal Growth Factor Receptor (EGFR) Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Epidermal Growth Factor Receptor (EGFR) Inhibitor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Epidermal Growth Factor Receptor (EGFR) Inhibitor companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Colorectal Cancer
- Lung Cancer
- Breast Cancer
- Others
Applications
- Clinic
- Hospital
- Research Institutes and Research Institutions
- Other
Companies covered
- Novartis AG
- Eli Lilly and Co.
- Amgen Inc.
- AstraZeneca Plc
- F. Hoffmann-La Roche Ltd.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Epidermal Growth Factor Receptor (EGFR) Inhibitor by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Colorectal Cancer
- 2.2.3 Lung Cancer
- 2.2.4 Breast Cancer
- 2.2.5 Others
- 2.3 Epidermal Growth Factor Receptor (EGFR) Inhibitor by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Clinic
- 2.3.3 Hospital
- 2.3.4 Research Institutes and Research Institutions
- 2.3.5 Other
- 2.4 Assumptions and Limitations
3 Epidermal Growth Factor Receptor (EGFR) Inhibitor Breakdown Data by Type
- 3.1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Historic Market Size by Type (2021-2026)
- 3.2 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Forecasted Market Size by Type (2027-2032)
4 Epidermal Growth Factor Receptor (EGFR) Inhibitor Breakdown Data by Application
- 4.1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Historic Market Size by Application (2021-2026)
- 4.2 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Perspective (2021-2032)
- 5.2 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Growth Trends by Region
- 5.2.1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Epidermal Growth Factor Receptor (EGFR) Inhibitor Historic Market Size by Region (2021-2026)
- 5.2.3 Epidermal Growth Factor Receptor (EGFR) Inhibitor Forecasted Market Size by Region (2027-2032)
- 5.3 Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Dynamics
- 5.3.1 Epidermal Growth Factor Receptor (EGFR) Inhibitor Industry Trends
- 5.3.2 Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Drivers
- 5.3.3 Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Challenges
- 5.3.4 Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Epidermal Growth Factor Receptor (EGFR) Inhibitor Players by Revenue
- 6.1.1 Global Top Epidermal Growth Factor Receptor (EGFR) Inhibitor Players by Revenue (2021-2026)
- 6.1.2 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Market Share by Players (2021-2026)
- 6.2 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Epidermal Growth Factor Receptor (EGFR) Inhibitor Head Office and Area Served
- 6.4 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Players, Product Type & Application
- 6.5 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Manufacturers Established Date
- 6.6 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size (2021-2032)
- 7.2 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Country (2021-2026)
- 7.4 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size (2021-2032)
- 8.2 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Country (2021-2026)
- 8.4 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size (2021-2032)
- 9.2 Asia-Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size (2021-2032)
- 10.2 South America Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Country (2021-2026)
- 10.4 South America Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size (2021-2032)
- 11.2 Middle East & Africa Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Novartis AG
- 12.1.1 Novartis AG Company Information
- 12.1.2 Novartis AG Business Overview
- 12.1.3 Novartis AG Revenue in Epidermal Growth Factor Receptor (EGFR) Inhibitor Business (2021-2026)
- 12.1.4 Novartis AG Epidermal Growth Factor Receptor (EGFR) Inhibitor Product Portfolio
- 12.1.5 Novartis AG Recent Developments
- 12.2 Eli Lilly and Co.
- 12.2.1 Eli Lilly and Co. Company Information
- 12.2.2 Eli Lilly and Co. Business Overview
- 12.2.3 Eli Lilly and Co. Revenue in Epidermal Growth Factor Receptor (EGFR) Inhibitor Business (2021-2026)
- 12.2.4 Eli Lilly and Co. Epidermal Growth Factor Receptor (EGFR) Inhibitor Product Portfolio
- 12.2.5 Eli Lilly and Co. Recent Developments
- 12.3 Amgen Inc.
- 12.3.1 Amgen Inc. Company Information
- 12.3.2 Amgen Inc. Business Overview
- 12.3.3 Amgen Inc. Revenue in Epidermal Growth Factor Receptor (EGFR) Inhibitor Business (2021-2026)
- 12.3.4 Amgen Inc. Epidermal Growth Factor Receptor (EGFR) Inhibitor Product Portfolio
- 12.3.5 Amgen Inc. Recent Developments
- 12.4 AstraZeneca Plc
- 12.4.1 AstraZeneca Plc Company Information
- 12.4.2 AstraZeneca Plc Business Overview
- 12.4.3 AstraZeneca Plc Revenue in Epidermal Growth Factor Receptor (EGFR) Inhibitor Business (2021-2026)
- 12.4.4 AstraZeneca Plc Epidermal Growth Factor Receptor (EGFR) Inhibitor Product Portfolio
- 12.4.5 AstraZeneca Plc Recent Developments
- 12.5 F. Hoffmann-La Roche Ltd.
- 12.5.1 F. Hoffmann-La Roche Ltd. Company Information
- 12.5.2 F. Hoffmann-La Roche Ltd. Business Overview
- 12.5.3 F. Hoffmann-La Roche Ltd. Revenue in Epidermal Growth Factor Receptor (EGFR) Inhibitor Business (2021-2026)
- 12.5.4 F. Hoffmann-La Roche Ltd. Epidermal Growth Factor Receptor (EGFR) Inhibitor Product Portfolio
- 12.5.5 F. Hoffmann-La Roche Ltd. Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst